Lanjee Medical Secures Tens of Millions in Series A+ Funding to Expand Blue Laser Product Portfolio
Blueray Medical
High-end Medical Device R&D Manufacturer
VCBeat has learned that Xi'an Blueray Medical Technologies, Ltd. (hereinafter referred to as “Blueray Medical”) recently completed a funding round led byHefei Zhonghe Opple Medical Health Industry FundLead Investor,Shaanxi Investment Growth FundParticipatingTens of millions in Series A+ fundingThe funds raised will be used for the research and development, clinical trials, and other activities related to a series of innovative products, including blue laser minimally invasive devices, integrated photodynamic diagnosis and treatment systems, and photobiomodulation therapies. Against the backdrop of a tightening macroeconomic environment and a cooling capital market, this financing fully demonstrates the capital market’s strong recognition of the team and its core pipeline.
Blueray Medical was established in June 2016 through the close collaboration between Dr. Mu Liyue, an expert in the industrialization of laser medicine, and Professor He Dalin from the First Affiliated Hospital of Xi’an Jiaotong University. Dedicated to the industrial translation of “medical-engineering integration,” the company focuses on the high-end medical laser sector, targeting large markets to research, develop, and manufacture internationally leading high-end laser medical devices with independent intellectual property rights.
In November 2021, the world’s first 30W blue laser surgical system developed by Blueray Medical obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA). Subsequently, in April 2022, the world’s most powerful 200W blue laser surgical system was also approved for market launch, making Blueray Medical the first company in the industry to achieve full independent research and development with proprietary intellectual property rights.
Blueray Medical 30W Blue Laser Surgical System
Blueray Medical 200W Blue Laser Surgical System
The product launch has attracted widespread attention from dozens of media outlets and industry publications, including Xinhua News Agency, China National Radio’s “Voice of China” program, People’s Daily, Science and Technology Daily, Health News, China News Service, CNR.cn, China Daily Online, and Shaanxi Province.
The Blue Laser Surgical System FeaturesHighest vaporization efficiency, minimal thermal injury, and a simple, easy-to-master surgical techniquesuch advantages, targetingDiseases of Natural Orifices Including the Prostate, Bladder, Oral Cavity, and Gynecological Uterus, offering innovative surgical solutions that significantly outperform high-frequency electrosurgical units and other lasers.
Director Zhao Yongwei, Taian Central HospitalVaporization treatment for a 120-gram enlarged prostate was completed in less than 20 minutes, safely, efficiently, and rapidly providing perfect relief from the patient’s symptoms. To preserve the sexual function of the 62-year-old patient, Director Zhao performed “blue laser prostate vaporization surgery with preservation of erectile and ejaculatory functions.” One month postoperatively, it was confirmed that the patient’s sexual function had been perfectly preserved.
Director Liu Hong, Chongqing Kanghua Hospital"Blue Laser Prostate Vaporization Surgery" was successfully performed in just 15 minutes on an 83-year-old patient with a history of coronary stenting and long-term anticoagulant therapy. Postoperatively, the bladder irrigation fluid was clear, with no bleeding observed.
Xianyang Central HospitalTransurethral blue laser vaporization of the prostate was performed on a 102-year-old high-risk patient. The patient returned safely to the ward postoperatively, with clear urine in the catheter. InXianyang Central HospitalAmong nearly 120 surgeries performed over three months, approximately 30% involved elderly, high-risk patients. The safe, efficient, and satisfactory therapeutic outcomes have received consistent acclaim from a broad patient base.
Blue laser prostate vaporization enables more patients to benefit from the convenience of advanced technology, extending its reach to primary care settings. It offers hope to high-risk and elderly patients while empowering physicians with greater confidence. Owing to the numerous advantages of blue laser technology, the product gained market recognition immediately upon its launch.Blueray Medical generated tens of millions of yuan in sales revenue in 2022, with its equipment adopted by over 140 hospitals and used in more than 1,200 surgical procedures.
The integrated photodynamic diagnosis and therapy product under development fully leverages the strong cytotoxic efficacy and tumor cell apoptosis-inducing properties of blue laser, addressing current clinical challenges such as low detection rates and high postoperative recurrence rates. It holds promise for reshaping the clinical diagnostic and therapeutic pathways for endometrial cancer and bladder cancer.
Mr. Tao Yuequn, Investment Committee Member of the Hefei Zhonghe Oupu Medical Health Industry Fund and Chairman of Autek China Co., Ltd.It stated: “As China’s healthcare reforms deepen and DRG (Diagnosis-Related Groups) and DIP (Diagnosis-Intervention Packet) payment systems are comprehensively promoted, clinical early diagnosis and treatment as well as minimally invasive therapies have continued to advance. Blueray Medical represents an outstanding entrepreneurial team that has emerged in recent years, characterized by ‘original hard-core technology-driven medical-engineering integration and industrial commercialization.’ Focusing on niche sectors such as minimally invasive surgery, photodynamic therapy, and photobiomodulation, the company is rooted in China while serving the global market, providing innovative ‘integrated diagnosis and treatment’ clinical solutions. We are delighted to participate in Blueray Medical’s development and believe that, leveraging the R&D capabilities and execution strength of its excellent team, the company will continue to deliver internationally competitive products in the field of laser-based minimally invasive procedures.”
Guo Jia, Managing Director of Shaanxi Growth FundIt is stated that Blueray Medical, as a paradigm of "medical-engineering integration," has creatively applied blue laser technology to the field of medical devices. By advancing this cutting-edge laser technology, which stems from Nobel Prize-winning physics research, the company has successively obtained two Class III medical device registration certificates and independently developed the world's most powerful medical laser equipment, earning widespread acclaim from clinicians. Building on this foundation, and under the leadership of its outstanding team, Blueray Medical leverages its laser energy platform to develop high-end laser products with significant clinical value, including multi-array minimally invasive surgical systems and integrated photodynamic diagnosis and therapy solutions. We are honored to participate in this endeavor, supporting the company's growth and benefiting more patients.
About Zhonghe Oupu
Hefei Zhonghe Oupu Medical Health Industry Fund (hereinafter referred to as “Zhonghe Oupu”) is a medical industry fund jointly established by Zhonghe Investment and the listed company Aier Eye Hospital’s competitor, Opcon Vision Technology (Stock Code: 300595). The management team possesses extensive experience in industrial investment and incubation resources. The fund focuses on investing in new therapies, new technologies, and innovative products within the healthcare sector, with particular emphasis on ophthalmology, dentistry, minimally invasive surgical equipment, and high-end consumables. It has already completed investments and strategic layout in more than ten high-quality medical enterprises.Zhonghe Investment is a fund management company specializing in investments in leading core technology enterprises and original technology platforms both domestically and internationally. Over the years, it has adopted a dual strategy of “fund of funds + direct investment.” In collaboration with listed companies and industrial capital such as Opcon Vision Technology, Anke Biotechnology, Ecoblue, and BAIC Industrial Investment, Zhonghe Investment has initiated and established more than ten funds. Its key areas of focus include medical innovation, semiconductors, new materials, intelligent connected vehicles, and new energy.
About the Growth Fund
Shaanxi Growth Enterprise Leading Fund Co., Ltd. (hereinafter referred to as “Growth Fund”), serving as the private equity investment platform under Shaanxi Investment Group and a representative of hard-tech venture capital, has established 13 market-oriented professional sub-funds and completed investments in over 30 high-quality enterprises, focusing on sectors such as high-end manufacturing, healthcare, military technology, and new materials. Currently, Shaanxi Growth continues to prioritize the development of the healthcare industry, with systematic layouts in biopharmaceuticals, biotechnology, and medical devices. The assets under management exceed RMB 6 billion, primarily concentrated in biopharmaceuticals, civil-military integration, and advanced manufacturing.
Recommended Reading: